These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 33030808

  • 1. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
    Desai D, Lepe M, Baloch ZW, Mandel SJ.
    Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
    [Abstract] [Full Text] [Related]

  • 2. Benign call rate and molecular test result distribution of ThyroSeq v3.
    Ohori NP, Landau MS, Carty SE, Yip L, LeBeau SO, Manroa P, Seethala RR, Schoedel KE, Nikiforova MN, Nikiforov YE.
    Cancer Cytopathol; 2019 Mar; 127(3):161-168. PubMed ID: 30561907
    [Abstract] [Full Text] [Related]

  • 3. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
    Shrestha RT, Evasovich MR, Amin K, Radulescu A, Sanghvi TS, Nelson AC, Shahi M, Burmeister LA.
    Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
    [Abstract] [Full Text] [Related]

  • 4. THADA-IGF2BP3 gene fusions in thyroid fine needle aspiration is involved in the pathway to "noninvasive follicular thyroid neoplasm with papillary-like nuclear features".
    Zand A, Kim TH, Rodriguez EF, Moatamed NA.
    Diagn Cytopathol; 2024 Nov; 52(11):627-632. PubMed ID: 38877784
    [Abstract] [Full Text] [Related]

  • 5. Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology.
    Kim SJ, Roh J, Baek JH, Hong SJ, Shong YK, Kim WB, Song DE.
    Cytopathology; 2017 Feb; 28(1):65-73. PubMed ID: 27245883
    [Abstract] [Full Text] [Related]

  • 6. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists.
    Padmanabhan V, Marshall CB, Akdas Barkan G, Ghofrani M, Laser A, Tolgay Ocal I, David Sturgis C, Souers R, Kurtycz DF.
    Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules.
    Scola WH, Linhares SM, Handelsman RS, Picado O, Khan ZF, Farrá JC, Lew JI.
    J Surg Res; 2021 Dec; 268():209-213. PubMed ID: 34358733
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Implementing noninvasive follicular thyroid neoplasm with papillary-like nuclear features may potentially impact the risk of malignancy for thyroid nodules categorized as AUS/FLUS and FN/SFN.
    Li W, Sciallis A, Lew M, Pang J, Jing X.
    Diagn Cytopathol; 2018 Feb; 46(2):148-153. PubMed ID: 29193839
    [Abstract] [Full Text] [Related]

  • 13. The Bethesda system for reporting thyroid cytopathology: an institutional experience of the outcome of indeterminate categories.
    Onder S, Firat P, Ates D.
    Cytopathology; 2014 Jun; 25(3):177-84. PubMed ID: 23998291
    [Abstract] [Full Text] [Related]

  • 14. A meta-analytic review of the Bethesda System for Reporting Thyroid Cytopathology: Has the rate of malignancy in indeterminate lesions been underestimated?
    Straccia P, Rossi ED, Bizzarro T, Brunelli C, Cianfrini F, Damiani D, Fadda G.
    Cancer Cytopathol; 2015 Dec; 123(12):713-22. PubMed ID: 26355876
    [Abstract] [Full Text] [Related]

  • 15. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
    Bellevicine C, Sgariglia R, Migliatico I, Vigliar E, D'Anna M, Nacchio MA, Serra N, Malapelle U, Bongiovanni M, Troncone G.
    Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
    [Abstract] [Full Text] [Related]

  • 16. Performance of repeat cytology with reflex ThyroSeq genomic classifier for indeterminant thyroid cytology.
    O'Conor CJ, Dash RC, Jones CK, Jiang XS.
    Cancer Cytopathol; 2022 Jun; 130(6):469-476. PubMed ID: 35045202
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Subclassification of Bethesda Atypical and Follicular Neoplasm Categories According to Nuclear and Architectural Atypia Improves Discrimination of Thyroid Malignancy Risk.
    Lim JXY, Nga ME, Chan DKH, Tan WB, Parameswaran R, Ngiam KY.
    Thyroid; 2018 Apr; 28(4):511-521. PubMed ID: 29596039
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Probability of malignancy as determined by ThyroSeq v3 genomic classifier varies according to the subtype of atypia.
    Gajzer DC, Tjendra Y, Kerr DA, Algashaamy K, Zuo Y, Menendez SG, Jorda M, Garcia-Buitrago M, Gomez-Fernandez C, Velez Torres JM.
    Cancer Cytopathol; 2022 Nov; 130(11):881-890. PubMed ID: 35775861
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.